Modification of mesenchymal stem cells for cardiac regeneration

Expert Opinion on Biological Therapy

Volumn 10, Issue 3, 2010, Pages 309-319

  Song, Heesang ^a,b   Song, Byeong Wook ^a   Cha, Min Ji ^a   Choi, In Geol ^a,c   Hwang, Ki Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Korea University   (South Korea)

Author keywords

Cardiac regenration; Cell adhesion; Cell survival; Mesenchymal stem cell

Indexed keywords

ANGIOPOIETIN 1; ATORVASTATIN; BONE MORPHOGENETIC PROTEIN 2; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYTOKINE; ESTROGEN; FIBROBLAST GROWTH FACTOR 2; HEAT SHOCK PROTEIN 70; PROTEIN BNIP3; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR; VASCULOTROPIN;

ANOIKIS; APOPTOSIS; CELL ADHESION; CELL DEATH; CELL HYPOXIA; CELL MANIPULATION; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; CELL TYPE; CELL VIABILITY; DNA MODIFICATION; EMBRYONIC STEM CELL; ENGRAFTMENT; EX VIVO STUDY; GENE OVEREXPRESSION; GENE TRANSFER; GENETIC TRANSFECTION; HEART; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEMATOPOIETIC STEM CELL; HUMAN; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MICROENVIRONMENT; MUSCLE REGENERATION; NONHUMAN; PATHOGENESIS; REVIEW; STEM CELL EXPANSION; TISSUE REPAIR; VIRAL GENE DELIVERY SYSTEM;

HEART; HEART DISEASES; HUMANS; MESENCHYMAL STEM CELLS; REGENERATION; STEM CELL TRANSPLANTATION;

EID: 76949087876     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590903455997     Document Type: Review

References (105)

1. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007;59:418-458
2. Lloyd-Jones DM. The risk of congestive heart failure: sobering lessons from the Framingham Heart Study. Curr Cardiol Rep 2001;3:184-190
3. Fonarow GC. Heart failure: recent advances in prevention and treatment. Rev Cardiovasc Med 2000;1:25-33,54
4. Penn MS, Mangi AA. Genetic enhancement of stem cell engraftment, survival, and efficacy. Circ Res 2008;102:1471-1482
5. Melo LG, Pachori AS, Kong D, et al. Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism. Circulation 2004;109:2386-2393
6. Chiu RC, Zibaitis A, Kao RL, et al. Cellular cardiomyoplasty: myocardial regeneration with satellite cell implantation. Ann Thorac Surg 1995;60:12-18
7. Li RK, Jia ZQ, Weisel RD, et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg 1996;62:654-660
8. Scorsin M, Hagege AA, Dolizy I, et al. Can cellular transplantation improve function in doxorubicin-induced heart failure? Circulation 1998;98:II151-5
9. Kehat I, Kenyagin-Karsenti D, Snir M, et al. Human embryonic stem cells can differentiate into myocytes with structural and functional properties of cardiomyocytes. J Clin Invest 2001;108:407-414
10. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999;103:697-705
11. Toma C, Pittenger MF, Cahill KS, et al. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002;105:93-98
12. Taylor DA, Atkins BZ, Hungspreugs P, et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat Med 1998;4:929-933
13. Wagers AJ, Weissman IL. Plasticity of adult stem cells. Cell 2004;116:639-648
14. Jiang Y, Jahagirdar BN, Reinhardt RL, et al. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 2002;418:41-49
15. Blanpain C, Horsley V, Fuchs E. Epithelial stem cells: turning over new leaves. Cell 2007;128:445-458
16. Kumar S, Chanda D, Ponnazhagan S. Therapeutic potential of genetically modified mesenchymal stem cells. Gene Ther 2008;15:711-715
17. Orlic D, Kajstura J, Chimenti S, et al. Bone marrow cells regenerate infarcted myocardium. Nature 2001;410:701-705
18. Chen SL, Fang WW, Ye F, et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004;94:92-95
19. Katritsis DG, Sotiropoulou PA, Karvouni E, et al. Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005;65:321-329
20. Schuleri KH, Boyle AJ, Hare JM. Mesenchymal stem cells for cardiac regenerative therapy. Handb Exp Pharmacol 2007;180:195-218
21. Heil M, Ziegelhoeffer T, Mees B, et al. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ Res 2004;94:573-574
22. Mathur A, Martin JF. Stem cells and repair of the heart. Lancet 2004;364:183-192
23. Zhang M, Methot D, Poppa V, et al. Cardiomyocyte grafting for cardiac repair: Graft cell death and anti-death strategies. J Mol Cell Cardiol 2001;33:907-921
24. Psaltis PJ, Zannettino AC, Worthley SG, et al. Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells 2008;26:2201-2210
25. Vertesaljai M, Piroth Z, Fontos G, et al. Drugs, gene transfer, signaling factors: a bench to bedside approach to myocardial stem cell therapy. Heart Fail Rev 2008;13:227-244
26. Tousoulis D, Briasoulis A, Antoniades C, et al. Heart regeneration: what cells to use and how? Curr Opin Pharmacol 2008;8:211-218
27. Rezai N, Walinski H, Kerjner A, et al. Methods for examining stem cells in post-ischemic and transplanted hearts. Methods Mol Med 2005;112:223-238
28. Laflamme MA, Murry CE. Regenerating the heart. Nat Biotechnol 2005;23:845-856
29. Gulati R, Simari RD. Cell therapy for acute myocardial infarction. Med Clin North Am 2007;91:769-85; xiii
30. Min JY, Yang Y, Sullivan MF, et al. Long-term improvement of cardiac function in rats after infarction by transplantation of embryonic stem cells. J Thorac Cardiovasc Surg 2003;125:361-369
31. Swijnenburg RJ, Tanaka M, Vogel H, et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation 2005;112:I166-72
32. Choi JH, Choi J, Lee WS, et al. Lack of additional benefit of intracoronary transplantation of autologous peripheral blood stem cell in patients with acute myocardial infarction. Circ J 2007;71:486-494
33. Popogeff IA, Murray MR. The form and behaviour of adult mammalian skeletal muscle in vitro. Anat Rec 1946;95:321-336
34. Pagani FD, DerSimonian H, Zawadzka A, et al. Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation. J Am Coll Cardiol 2003;41:879-888
35. Menasché P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation 2008;117:1189-1200
36. Asahara T, Kawamoto A. Endothelial progenitor cells for postnatal vasculogenesis. Am J Physiol Cell Physiol 2004;287:C572-9
37. Schmidt-Lucke C, Rössig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005;111:2981-2987
38. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiospherederived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007;115:896-908
39. Seandel M, James D, Shmelkov SV, et al. Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature 2007;449:346-350
40. Guan K, Nayernia K, Maier LS, et al. Pluripotency of spermatogonial stem cells from adult mouse testis. Nature 2006;440:1199-1203
41. Friedenstein AJ. Osteogenetic activity of transplanted transitional epithelium. Acta Anat (Basel) 1961;45:31-59
42. Muraglia A, Cancedda R, Quarto R. Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 2000;113:1161-1166
43. Graf T. Differentiation plasticity of hematopoietic cells. Blood 2002;99:3089-3101
44. Bartholomew A, Sturgeon C, Siatskas M, et al. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 2002;30:42-48
45. Devine SM, Bartholomew AM, Mahmud N, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001;29:244-255
46. Devine SM, Cobbs C, Jennings M, et al. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood 2003;101:2999-3001
47. Ghosh-Choudhury N, Abboud SL, Mahimainathan L, et al. Phosphatidylinositol 3- kinase regulates bone morphogenetic protein-2 (BMP-2)-induced myocyte enhancer factor 2A-dependent transcription of BMP-2 gene in cardiomyocyte precursor cells. J Biol Chem 2003;278:21998-22005
48. Freyman T, Polin G, Osman H, et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006;27:1114-1122
49. Suzuki K, Murtuza B, Beauchamp JR, et al. Dynamics and mediators of acute graft attrition after myoblast transplantation to the heart. FASEB J 2004;18:1153-1155
50. Nakamura Y, Yasuda T, Weisel RD, et al. Enhanced cell transplantation: preventing apoptosis increases cell survival and ventricular function. Am J Physiol Heart Circ Physiol 2006;291:H939-47
51. Sadek HA, Martin CM, Latif SS, et al. Bone-marrow-derived side population cells for myocardial regeneration. J Cardiovasc Trans Res 2009;2:173-181
52. Michel JB. Anoikis in the cardiovascular system: known and unknown extracellular mediators. Arterioscler Thromb Vasc Biol 2003;23:2146-2154
53. Ingber DE. Mechanical signaling and the cellular response to extracellular matrix in angiogenesis and cardiovascular physiology. Circ Res 2002;91:877-887
54. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008;76(11):1352-1364
55. Mylotte LA, Duffy AM, Murphy M, et al. Metabolic flexibility permits mesenchymal stem cell survival in an ischemic environment. Stem Cells 2008;26:1325-1336
56. Guo J, Lin GS, Bao CY, et al. Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Inflammation 2007;30:97-104
57. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-626
58. Gartner S, Kaplan HS. Long-term culture of human bone marrow cells. Proc Natl Acad Sci USA 1980;77:4756-4759
59. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008;76:1352-1364
60. Song H, Chang W, Lim S, et al. Tissue transglutaminase is essential for integrin-mediated survival of bone marrow-derived mesenchymal stem cells. Stem Cells 2007;25:1431-1438
61. Memon IA, Sawa Y, Fukushima N, et al. Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J Thorac Cardiovasc Surg 2005;130:1333-1341
62. Sáenz-Morales D, Conde E, Escribese MM, et al. ERK1/2 mediates cytoskeleton and focal adhesion impairment in proximal epithelial cells after renal ischemia. Cell Physiol Biochem 2009;23:285-294
63. Zhu WG, Li S, Lin LQ, et al. Vascular oxidative stress increases dendritic cell adhesion and transmigration induced by homocysteine. Cell Immunol 2009;254:110-116
64. Yao EH, Yu Y, Fukuda N. Oxidative stress on progenitor and stem cells in cardiovascular diseases. Curr Pharm Biotechnol 2006;7:101-108
65. Pelegrin P, Surprenant A. Dynamics of macrophage polarization reveal new mechanism to inhibit IL-1beta release through pyrophosphates. EMBO J 2009;28:2114-2127
66. Frangogiannis NG. Targeting the inflammatory response in healing myocardial infarcts. Curr Med Chem 2006;13(16):1877-1893
67. Hahn JY, Cho HJ, Kang HJ, et al. Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol 2008;51:933-943
68. Lu G, Haider HK, Jiang S, et al. Sca-1+ stem cell survival and engraftment in the infarcted heart: dual role for preconditioning-induced connexin-43. Circulation 2009;119:2587-2596
69. Chang W, Song BW, Lim S, et al. Mesenchymal stem cells pretreated with delivered Hph-1-Hsp70 protein are protected from hypoxia-mediated cell death and rescue heart functions from myocardial injury. Stem Cells 2009;27(9):2283-2292
70. Ray R, Novotny NM, Crisostomo PR, et al. Sex steroids and stem cell function. Mol Med 2008;14:493-501
71. Yang YJ, Qian HY, Huang J, et al. Atorvastatin treatment improves survival and effects of implanted mesenchymal stem cells in post-infarct swine hearts. Eur Heart J 2008;29:1578-1590
72. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J 2006;20:661-669
73. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med 2003;9:1195-1201
74. Li W, Ma N, Ong LL, et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells 2007;25:2118-2127
75. Kofidis T, de Bruin JL, Yamane T, et al. Insulin-like growth factor promotes engraftment, differentiation, and functional improvement after transfer of embryonic stem cells for myocardial restoration. Stem Cells 2004;22:1239-1245
76. Song H, Kwon K, Lim S, et al. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol Cells 2005;19:402-407
77. Tang YL, Tang Y, Zhang YC, et al. Improved graftmesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol 2005;46:1339-1350
78. Markel TA, Wang Y, Herrmann JL, et al. VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function. Am J Physiol Heart Circ Physiol 2008;295:H2308-14
79. Kutschka I, Chen IY, Kofidis T, et al. Collagen matrices enhance survival of transplanted cardiomyoblasts and contribute to functional improvement of ischemic rat hearts. Circulation 2006;114:I167-73
80. Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007;25:1015-1024
81. Copland IB, Lord-Dufour S, Cuerquis J, et al. Improved autograft survival of mesenchymal stromal cells by plasminogen activator inhibitor 1 inhibition. Stem Cells 2009;27:467-477
82. Matter ML, Ruoslahti EA. Signaling pathway from the alpha5beta1 and alphavbeta3 integrins that elevates bcl-2 transcription. J Biol Chem 2001;276:27757-27763
83. Akimov SS, Krylov D, Fleischman LF, et al. Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin. J Cell Biol 2000;148:825-838
84. Persad S, Attwell S, Gray V, et al. Regulation of protein kinase B/Akt-serine 473 phosphorylation by integrin-linked kinase: critical roles for kinase activity and amino acids arginine 211 and serine 343. J Biol Chem 2001;276:27462-27469
85. Cho HJ, Youn SW, Cheon SI, et al. Regulation of endothelial cell and endothelial progenitor cell survival and vasculogenesis by integrinlinked kinase. Arterioscler Thromb Vasc Biol 2005;25:1154-1160
86. White DE, Cardiff RD, Dedhar S, et al. Mammary epithelialspecific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 2001;20:7064-7072
87. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995;268:233-239
88. Schwartz MA, Schaller MD, Ginsberg MH. Integrins: emerging paradigms of signal transduction. Annu Rev Cell Dev Biol 1995;11:549-599
89. Wehrle-Haller B, Imhof BA. The inner lives of focal adhesions. Trends Cell Biol 2002;12(8):382-389
90. Imhof BA, Aurrand-Lions M. Adhesion mechanisms regulating the migration of monocytes. Nat Rev Immunol 2004;4:432-444
91. Yang J, Zhou W, Zheng W, et al. Effects of myocardial transplantation of marrow mesenchymal stem cells transfected with vascular endothelial growth factor for the improvement of heart function and angiogenesis after myocardial infarction. Cardiology 2007;107:17-29
92. Shujia J, Haider HK, Idris NM, et al. Stable therapeutic effects of mesenchymal stem cell-based multiple gene delivery for cardiac repair. Cardiovasc Res 2008;77:525-533
93. Cheng Z, Ou L, Zhou X, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther 2008;16:571-579
94. Zeng B, Chen H, Zhu C, et al. Effects of combined mesenchymal stem cells and heme oxygenase-1 therapy on cardiac performance. Eur J Cardiothorac Surg 2008;34:850-856
95. Song SW, Chang W, Song BW, et al. Integrin-linked kinase is required in hypoxic mesenchymal stem cells for strengthening cell adhesion to ischemic myocardium. Stem Cells 2009;27:1358-1365
96. Bao C, Guo J, Lin G, et al. TNFR gene-modified mesenchymal stem cells attenuate inflammation and cardiac dysfunction following MI. Scand Cardiovasc J 2008;42:56-62
97. Gao F, He T, Wang H, et al. A promising strategy for the treatment of ischemic heart disease: Mesenchymal stem cell-mediated vascular endothelial growth factor gene transfer in rats. Can J Cardiol 2007;23:891-898
98. Matsumoto R, Omura T, Yoshiyama M, et al. Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol 2005;25:1168-1173
99. Guo Y, He J, Wu J, et al. Locally overexpressing hepatocyte growth factor prevents post-ischemic heart failure by inhibition of apoptosis via calcineurin-mediated pathway and angiogenesis. Arch Med Res 2008;39:179-188
100. Pasha Z, Wang Y, Sheikh R, et al. Preconditioning enhances cell survival and differentiation of stem cells during transplantation in infarcted myocardium. Cardiovasc Res 2008;77:134-142
101. Maurel A, Azarnoush K, Sabbah L, et al. Can cold or heat shock improve skeletal myoblast engraftment in infarcted myocardium? Transplantation. 2005;80:660-665
102. He A, Jiang Y, Gui C, et al. The antiapoptotic effect of mesenchymal stem cell transplantation on ischemic myocardium is enhanced by anoxic preconditioning. Can J Cardiol 2009;25:353-358
103. Shabbir A, Zisa D, Suzuki G, et al. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am J Physiol Heart Circ Physiol 2009;296:H1888-97
104. Chen J, Baydoun AR, Xu R, et al. Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis. Stem Cells 2008;26:135-145
105. Chen TL, Wang JA, Shi H, et al. Cyclosporin A pre-incubation attenuates hypoxia/reoxygenation-induced apoptosis in mesenchymal stem cells. Scand J Clin Lab Invest 2008;68:585-593